Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:MLNT

Melinta Therapeutics (MLNT) Stock Price, News & Analysis

Melinta Therapeutics logo

About Melinta Therapeutics Stock (NASDAQ:MLNT)

Key Stats

Today's Range
N/A
50-Day Range
$0.35
$0.50
52-Week Range
N/A
Volume
N/A
Average Volume
713,628 shs
Market Capitalization
$6.88 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Melinta Therapeutics, Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes various anti-infectives for the treatment of bacterial infectious diseases in North America. It offers Baxdela, a monotherapy treatment of adult patients with acute bacterial skin or skin structure infections (ABSSSIs); Vabomere, an IV antibiotic used in treatment of gram-negative infections; Orbactiv, an IV antibiotic of the lipoglycopeptide class for the treatment of adult patients with ABSSSIs; and Minocin, a IV antibiotic of the tetracycline class with activity against gram-positive and gram-negative pathogens. The company has license agreements with Yale University, Medical Research Council, Wakunaga Pharmaceutical Co., Ltd., and CyDex Pharmaceuticals, Inc. Melinta Therapeutics, Inc. was founded in 2000 and is headquartered in New Haven, Connecticut.

Receive MLNT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Melinta Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

MLNT Stock News Headlines

Sell NVDA Now?
Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's what that means for your money. Billionaire Wall Street investors are quietly offloading millions of shares. What do they know that you don't? It's arguably the most popular stock in the world. Now, one 50-year Wall Street legend says its day in the sun could finally be coming to an end. Last year, he warned of two stocks that went on to crash 60%.
SWTX SpringWorks Therapeutics, Inc.
See More Headlines

MLNT Stock Analysis - Frequently Asked Questions

Melinta Therapeutics Inc (NASDAQ:MLNT) released its quarterly earnings results on Tuesday, November, 12th. The biotechnology company reported ($15.67) earnings per share for the quarter, missing analysts' consensus estimates of ($2.55) by $13.12. The biotechnology company earned $15.87 million during the quarter, compared to analyst estimates of $15.51 million. Melinta Therapeutics had a negative net margin of 393.39% and a negative trailing twelve-month return on equity of 101.29%.

Shares of Melinta Therapeutics reverse split on the morning of Friday, February 22nd 2019. The 1-5 reverse split was announced on Thursday, February 21st 2019. The number of shares owned by shareholders was adjusted after the market closes on Thursday, February 21st 2019. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some other companies that Melinta Therapeutics investors own include Cara Therapeutics (CARA), Clearside Biomedical (CLSD), Chimerix (CMRX), Aerie Pharmaceuticals (AERI), Advanced Micro Devices (AMD), Bristol-Myers Squibb (BMY) and Gilead Sciences (GILD).

Company Calendar

Last Earnings
11/12/2019
Today
11/02/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:MLNT
CUSIP
15130J10
Fax
N/A
Employees
290
Year Founded
N/A

Profitability

Net Income
$-157,190,000.00
Net Margins
-393.39%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$96.43 million
Book Value
$16.96 per share

Miscellaneous

Free Float
N/A
Market Cap
$6.88 million
Optionable
Optionable
Beta
4.16
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

This page (NASDAQ:MLNT) was last updated on 11/2/2024 by MarketBeat.com Staff
From Our Partners